Literature DB >> 18675506

Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice.

Feng Tian1, Longxin Wang, Weijun Qin, Fuli Wang, Bin Song, Yu Li, Weihong Wen, Zheng Zhang, Kaichang Zhu, Qiang Zhang, Chung Lee, Weide Zhong, Yinglu Guo, He Wang.   

Abstract

Dendritic cells (DCs) have been widely used as cancer vaccines. However, their functional abilities have often been suppressed by tumor-secreted immunosuppressants such as transforming growth factor-beta (TGF-beta). We developed a new strategy using a TGF-beta insensitive DC as cancer vaccine. The effect of this vaccine was tested in a murine pulmonary metastases model of renal carcinoma (Renca). Tumor lysate-pulsed DCs (TP-DCs) were infected with retrovirus containing gene of dominant negative TGF-beta type II receptor (TbetaRIIDN) and thus made TGF-beta insensitive. Vaccination of the mice bearing Renca pulmonary metastases with the TbetaRIIDN TP-DC induced powerful tumor-specific cytotoxic T lymphocyte (CTL) responses, suppressed pulmonary metastases, and prolonged survival times. These results suggest TGF-beta-insensitive TP-DC vaccine can be used to enhance the antitumor efficacy of DC vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18675506     DOI: 10.1016/j.canlet.2008.06.025

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells.

Authors:  Jon G Quatromoni; Eiji Suzuki; Olugbenga Okusanya; Brendan F Judy; Pratik Bhojnagarwala; Ollin Venegas; Evgeniy Eruslanov; Jarrod D Predina; Steven M Albelda; Sunil Singhal
Journal:  BMC Immunol       Date:  2013-07-17       Impact factor: 3.615

2.  T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy.

Authors:  Jon G Quatromoni; Yue Wang; Dan D Vo; Lilah F Morris; Ali R Jazirehi; William McBride; Talal Chatila; Richard C Koya; James S Economou
Journal:  J Transl Med       Date:  2012-06-19       Impact factor: 5.531

Review 3.  Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity.

Authors:  Kristian M Hargadon
Journal:  J Clin Med       Date:  2016-08-31       Impact factor: 4.241

Review 4.  The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.

Authors:  Barbara Seliger; Chiara Massa
Journal:  Front Immunol       Date:  2013-12-02       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.